FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer By Ogkologos - March 23, 2026 306 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FX-909-CLINPRO-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Pembrolizumab Plus Weekly Paclitaxel, With Or Without Bevacizumab, Improves OS in... April 23, 2026 Clinical Trials in Genitourinary Cancers: MAGNITUDE, PROOF 302, and CYTOSHRINK December 21, 2020 Gynaecological Cancers: Immunotherapy and Novel Targeted Drug Appear Beneficial in Group... September 13, 2024 Supplemental Breast Cancer Imaging Techniques Could Lead to Earlier Detection of... May 28, 2025 Load more HOT NEWS Dealing With Fears Longer Duration of Treatment with ICIs Associated with a Higher Rate... A Vaccine to Treat Non-Hodgkin Lymphoma Advancing in Clinical Trials Answers to Your Questions About the COVID-19 Vaccine
